ArticleFrontiers in medicine2025
Bronchiectasis morphology and hemoptysis recurrence after bronchial artery embolization: a cohort study using inverse probability of treatment weighting.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hemoptysis risk in hospitalized patients with bronchiectasis: development and external validation of a clinical prediction model.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemoptysis is a serious and often life-threatening symptom associated with various pulmonary conditions, with bronchiectasis being a common cause. Bronchial artery embolization (BAE) is an effective intervention for managing hemoptysis, yet recurrence rates remain high. Several studies have identified general risk factors for recurrence. However, the role of bronchiectasis subtypes in predicting long-term outcomes after BAE has not been thoroughly explored. Objective: To assess the association between cystic bronchiectasis and the risk of hemoptysis recurrence following BAE, compared to non-cystic bronchiectasis subtypes. Methods: This retrospective cohort study included 168 adults treated with BAE for hemoptysis due to bronchiectasis from January 2017 to April 2022. Bronchiectasis was classified as cystic or non-cystic according to the Reid morphological criteria. Baseline differences between groups were adjusted using inverse probability of treatment weighting (IPTW). Results: Patients with cystic bronchiectasis exhibited a significantly higher recurrence risk than those with non-cystic bronchiectasis before and after IPTW adjustment (HR = 2.62; 95% CI, 1.42-4.82; Conclusions: Cystic bronchiectasis is a significant independent predictor of hemoptysis recurrence following BAE. These findings suggest bronchiectasis morphology, especially cystic changes, should be recognized as an important prognostic factor when selecting candidates for BAE and planning long-term management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.